- The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc’s drug for relieving migraine headaches after their onset.
The drug, Ubrelvy, is the first oral version of a new class of drugs called calcitonin gene-related peptide inhibitors to win the FDA's approval for treating the neurological disease. Allergan, which has been pushing to solidify its presence in the migraine market, is developing another oral CGRP inhibitor for migraine prevention, called atogepant.
Offering drugs for both prevention and treatment of migraine, Allergan will have “the most complete” product line for neurologists and primary care physicians who are managing the condition, Chief Commercial Officer Bill Meury told Reuters.Rival products such as Amgen Inc and Novartis AG’s Aimovig, Eli Lilly and Co’s Emgality and Teva Pharmaceutical Industries Ltd’s Ajovy won approval within months of each other last year, signaling a threat to Botox’s position as a therapeutic.
Good to know
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Everything You Never Wanted to Know About Spiders, In Case One Bites YouSpider bites in the U.S. are typically harmless, but know your spider bite symptoms and types of spiders to make sure you get the proper treatment.
Source: Health - 🏆 396. / 53 Read more »
Source: etnow - 🏆 696. / 51 Read more »